This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Norgine Limited

Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS
Telephone: +44 (0)1895 826 600
Fax: +44 (0)1895 825 865
E-mail:
Medical Information e-mail: medinfo@norgine.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 17/06/2013
SPC Movicol 13.8g sachet, powder for oral solution


Go to top of the page
1. Name of the medicinal product

MOVICOL® 13.8g sachet, powder for oral solution


Go to top of the page
2. Qualitative and quantitative composition

Each sachet of MOVICOL contains the following active ingredients:

Macrogol 3350

13.125 g

Sodium chloride

350.7 mg

Sodium bicarbonate

178.5 mg

Potassium chloride

46.6 mg

The content of electrolyte ions per sachet when made up to 125 ml of solution is as follows:

Sodium

65 mmol/l

Chloride

53 mmol/l

Potassium

5.4 mmol/l

Bicarbonate

17 mmol/l

For excipients, see Section 6.1


Go to top of the page
3. Pharmaceutical form

Powder for oral solution. Free flowing white powder.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

For the treatment of chronic constipation. MOVICOL is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon.


Go to top of the page
4.2 Posology and method of administration

Chronic constipation

A course of treatment for constipation with MOVICOL does not normally exceed 2 weeks, although this can be repeated if required.

As for all laxatives, prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medication in particular opioids and antimuscarinics.

Adults, adolescents and the elderly: 1 –3 sachets daily in divided doses, according to individual response.

For extended use, the dose can be adjusted down to 1 or 2 sachets daily.

Children (below 12 years old): Not recommended. Alternative MOVICOL products are available for children.

Faecal impaction

A course of treatment for faecal impaction with MOVICOL does not normally exceed 3 days.

Adults, adolescents and the elderly: 8 sachets daily, all of which should be consumed within a 6 hour period.

Children (below 12 years old): Not recommended. Alternative MOVICOL products are available for children.

Patients with impaired cardiovascular function: For the treatment of faecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.

Patients with renal insufficiency: No dosage change is necessary for treatment of either constipation or faecal impaction.

Administration

Each sachet should be dissolved in 125 ml water. For use in faecal impaction 8 sachets may be dissolved in 1 litre of water.


Go to top of the page
4.3 Contraindications

Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease and ulcerative colitis and toxic megacolon.

Hypersensitivity to the active ingredients or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Diagnosis of impaction/faecal loading of the rectum should be confirmed by physical or radiological examination of the abdomen and rectum.

Mild adverse drug reactions are possible as indicated in Section 4.8. If patients develop any symptoms indicating shifts of fluids/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) MOVICOL should be stopped immediately and electrolytes measured, and any abnormality should be treated appropriately.

The absorption of other medicinal products could transiently be reduced due to an increase in gastro-intestinal transit rate induced by MOVICOL (see section 4.5).


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Macrogol raises the solubility of medicinal products that are soluble in alcohol and relatively insoluble in water.

There is a possibility that the absorption of other medicinal products could be transiently reduced during use with MOVICOL (see section 4.4).There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics.


Go to top of the page
4.6 Fertility, pregnancy and lactation

Pregnancy

There are limited amount of data from the use of MOVICOL in pregnant women. Studies in animals have shown indirect reproductive toxicity (see section 5.3). Clinically, no effects during pregnancy are anticipated, since systemic exposure to macrogol 3350 is negligible.

MOVICOL can be used during pregnancy.

Breastfeeding

No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol 3350 is negligible.

MOVICOL can be used during breast-feeding.

Fertility

There are no data on the effects of MOVICOL on fertility in humans. There were no effects on fertility in studies in male and female rats (see section 5.3).


Go to top of the page
4.7 Effects on ability to drive and use machines

MOVICOL has no influence on the ability to drive and use machines.


Go to top of the page
4.8 Undesirable effects

Reactions related to the gastrointestinal tract occur most commonly.

These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of MOVICOL. Mild diarrhoea usually responds to dose reduction.

The frequency of the adverse effects is not known as it cannot be estimated from the available data.

System Order Class

Adverse Event

Immune system disorders

Allergic reactions, including anaphylaxis, angioedema, dyspnoea, rash, erythema, urticaria, and pruritus.

Metabolism and nutrition disorders

Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia.

Nervous system disorders

Headache

Gastrointestinal disorders

Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anal discomfort.

General disorders and administration site conditions

Peripheral oedema.


Go to top of the page
4.9 Overdose

Severe pain or distension can be treated by nasogastric aspiration. Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Osmotically acting laxatives.

ATC code: A06A D65

Macrogol 3350 acts by virtue of its osmotic action in the gut, which induces a laxative effect. Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defecation. Electrolytes combined with macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in faecal water without net gain or loss of sodium, potassium and water.

For the indication of faecal impaction controlled comparative studies have not been performed with other treatments (e.g. enemas). In a non-comparative study in 27 adult patients, MOVICOL cleared the faecal impaction in 12/27 (44%) after 1 day's treatment; 23/27 (85%) after 2 days' treatment and 24/27 (89%) at the end of 3 days.

Clinical studies in the use of MOVICOL in chronic constipation have shown that the dose needed to produce normal formed stools tends to reduce over time. Many patients respond to between 1 and 2 sachets a day, but this dose should be adjusted depending on individual response.


Go to top of the page
5.2 Pharmacokinetic properties

Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.


Go to top of the page
5.3 Preclinical safety data

Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential, based on conventional studies of pharmacology, repeated dose toxicity and genotoxicity.

There were no direct embryotoxic or teratogenic effects in rats even at maternally toxic levels that are a multiple of 66 x the maximum recommended dose in humans for chronic constipation and 25 x for faecal impaction. Indirect embryofetal effects, including reduction in fetal and placental weights, reduced fetal viability, increased limb and paw hyperflexion and abortions, were noted in the rabbit at a maternally toxic dose that was 3.3 x the maximum recommended dose in humans for treatment of chronic constipation and 1.3 x for faecal impaction. Rabbits are a sensitive animal test species to the effects of GI-acting substances and the studies were conducted under exaggerated conditions with high dose volumes administered, which are not clinically relevant. The findings may have been a consequence of an indirect effect of MOVICOL related to poor maternal condition as the result of an exaggerated pharmacodynamic response in the rabbit. There was no indication of a teratogenic effect.

There are long-term animal toxicity and carcinogenicity studies involving macrogol 3350. Results from these and other toxicity studies using high levels of orally administered high molecular weight macrogols provide evidence of safety at the recommended therapeutic dose.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Acesulfame potassium (E950)

Lime and lemon flavour*

*(Lime and lemon flavour contains the following constituents: acacia solids, maltodextrin, lime oil, lemon oil, citral, citric acid and water).


Go to top of the page
6.2 Incompatibilities

None are known.


Go to top of the page
6.3 Shelf life

3 years.

Reconstituted solution: 6 hours.


Go to top of the page
6.4 Special precautions for storage

Sachet: Do not store above 25°C.

Reconstituted solution: Store at 2 - 8°C (in a refrigerator and covered).


Go to top of the page
6.5 Nature and contents of container

Sachets: laminate consisting of four layers: low density polyethylene, aluminium, low density polyethylene and paper.

Pack sizes: boxes of 2, 6, 8, 10, 20, 30, 50, 60 or 100 sachets.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

Any unused solution should be discarded within 6 hours.


Go to top of the page
7. Marketing authorisation holder

Norgine Limited

Norgine House

Widewater Place

Moorhall Road

Harefield

Uxbridge

Middlesex UB9 6NS

United Kingdom


Go to top of the page
8. Marketing authorisation number(s)

PL 00322/0070


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

18th December 1995 / 18th December 2005


Go to top of the page
10. Date of revision of the text

May 2013



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/1244/SPC/